Purchase Order 75F40123P00230
Award Date 9/15/23
Potential Completion Date 3/29/24
Potential Value $56K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Folsom, CA 95630, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Food and Drug Administration (FDA) awarded a $47,470.00 firm-fixed price purchase order contract to Stemexpress, LLC (doing business as CGT Global), a small disadvantaged woman-owned business, to provide human donor blood for the development of bioassays using peripheral blood mononuclear cells (PBMC) and/or isolated immune cells. The contract has an ultimate completion date of August 31, 2025 and does not utilize a set-aside. Stemexpress, a provider of human biological samples, has...
- This $112,095.00 firm fixed-price purchase order contract was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Stemcell Technologies Inc., a foreign-owned for-profit organization, to provide a STEMvision Instrument. The STEMvision Instrument is a computer-operated bench-top instrument that images and quantifies hematopoietic colonies in colony forming unit (CFU) assays of human bone marrow, peripheral blood, and cord blood. This instrument will...
- The U.S. Food and Drug Administration (FDA) awarded a Firm Fixed Price Purchase Order contract worth $94,003.45 to Charles River Laboratories Cell Solutions, Inc. for the provision of human primary CD34+ hematopoietic stem and progenitor cells. This contract supports the FDA's Center for Biologics Evaluation and Research (CBER), Division of Cell and Gene Therapy (DCGT) in conducting critical path research to develop and promote technology for the regulation of cellular and genetic...
- The Food and Drug Administration awarded a firm fixed-price purchase order to Charles River Laboratories Cell Solutions, Inc. for CD34+ stem/progenitor cells, with a ceiling value of $24,969.00. The contract, awarded on August 31, 2021, is scheduled for ultimate completion by March 12, 2026, and will be performed in Silver Spring, Maryland. No set-aside designation was applied to this award. This modification to the existing contract serves to de-obligate funds and close out the purchase...
- This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of human induced pluripotent stem cell-derived cells. The $26,680 contract is to provide specialized cell cultures, including cardiomyocytes, neurons, astrocytes, and hepatocytes, to support the FDA's active research program. The award has no set-aside designation and is a sole-source award,...
- This federal contract award was granted to Stemcell Technologies Inc., a subsidiary of the Canadian biotechnology company Stemcell Technologies, by the Department of Health and Human Services (HHS). The contract, worth $24,908.80, is a firm fixed-price purchase order for the company to provide a range of specialized biological materials, laboratory supplies, scientific equipment, and proprietary products to support biomedical research initiatives across various HHS agencies, including the...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Laboratory Corporation Of America Holdings, a global life sciences leader, for $115,000 to perform high-resolution, gene-based HLA typing of 1,000 patient samples. The requirement is to support the FDA's Center for Biologics Evaluation and Research (CBER) hemophilia genetic project. This is an open competition contract, with no set-aside designation. The award...
- This is a $99,500.00 firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The contract is for the supply of iCell Cardiomyocytes, a specialized cell product used in biomedical research, drug development, and toxicology screening. The contract has...
- The U.S. Food and Drug Administration (FDA) awarded a $98,725.00 firm fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. (FCDI), a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract is for the purchase of cardiomyocytes, which are heart muscle cells, and does not have a set-aside designation. FCDI is a key supplier of specialized cell products, particularly to the Department of Health and Human...
- This is a firm fixed price delivery order issued by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Spaulding Clinical Research, LLC, a self-certified small disadvantaged business. The $6,561,386.54 contract is for a range of clinical and laboratory applied regulatory science services that support the FDA's regulatory science programs and decision-making across product lifecycles. Services include conducting clinical...